All In Biotech

Drug Trial Radar · NCT01077843

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in a Cohort of Patients With Ankylosing Spondylitis (AS) in the UK, France and Germany

Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27,381

Actual

Start

Aug 17, 2009

Primary completion

Jul 1, 2015

Study completion Jul 1, 2015

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Mar 1, 2010

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a population-based cohort of patients with ankylosing spondylitis (AS) from general medical practices in the UK, France, and Germany with a nested case control component to assess associations between drug exposures of interest and clinical outcomes relevant to patients using cyclooxygenase-2 (COX-2) inhibitors / nonsteroidal anti-inflammatory drugs (NSAIDS). The main objective of the study is to describe in European participants with AS: 1) the use of etoricoxib 2) characteristics of those who use etoricoxib. 3) the safety profile of etoricoxib and other anti-inflammatory therapies with respect to specific clinical outcomes of interest relative to non-use of these medications and relative to each other.

Conditions

  • Ankylosing Spondylitis

Interventions

  • EtoricoxibDrug

    Cox-2 inhibitor

  • Other Cox-2 inhibitorsDrug

    Cox-2 inhibitor

  • Other Non-selective NSAIDsDrug

    Non-selective NSAID

  • No anti-inflammatory treatmentOther

    No anti-inflammatory prescription

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of gastrointestinal ulcer, perforation or bleedingTime frame: First incident event for a given patient through 31-December-2017
  2. Incidence rate of fatal or non-fatal acute myocardial infarction or unstable angina pectorisTime frame: First incident event for a given patient through 31-December-2017
  3. Incidence rate of fatal or non-fatal ischemic stroke, or transient ischemic attackTime frame: First incident event for a given patient through 31-December-2017
  4. Incidence rate of fatal or non-fatal hemorrhagic strokeTime frame: First incident event for a given patient through 31-December-2017
  5. Incidence rate of deep venous thrombosis, pulmonary embolism, or peripheral arterial embolism or thrombosisTime frame: First incident event for a given patient through 31-December-2017
  6. Incidence rate of acute renal impairment or failureTime frame: First incident event for a given patient through 31-December-2017
  7. Incidence rate of hypertensionTime frame: First incident event for a given patient through 31-December-2017
  8. Incidence rate of congestive heart failure or left ventricular dysfunctionTime frame: First incident event for a given patient through 31-December-2017
  9. Incidence rate of sudden or unexplained deathTime frame: First incident event for a given patient through 31-December-2017

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.